跳至主要内容
临床试验/JPRN-jRCT2080222300
JPRN-jRCT2080222300未知2 期

A Phase 2B/3 Open-label Study of EPI-743 in Children with Leigh Syndrome

Sumitomo Dainippon Pharma Co., Ltd.0 个研究点目标入组 5 人开始时间: 2013年11月21日最近更新:

试验速览

阶段
2 期
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 <= 17age old(—)
性别
All

入选标准

  • - Clinical and MRI diagnosis of Leigh syndrome

排除标准

  • - Allergy to EPI-743 or sesame oil
  • - Allergy to vitamin E
  • - Diagnosis of any other concurrent inborn error of metabolism

研究者

相似试验

进行中(未招募)
不适用
A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to the last prior therapy for their disease. - E7389-G000-211ocally advanced or metastatic breast cancerMedDRA version: 8.1Level: PTClassification code 10055113
EUCTR2005-003656-35-ATEisai Limited300
进行中(未招募)
不适用
A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to the last prior therapy for their disease. - E7389-G000-211
EUCTR2005-003656-35-DEEisai Limited300
进行中(未招募)
不适用
A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to the last prior therapy for their disease. - E7389-G000-211
EUCTR2005-003656-35-ESEisai Limited300
进行中(未招募)
不适用
A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to the last prior therapy for their disease. - E7389-G000-211
EUCTR2005-003656-35-BEEisai Limited300
进行中(未招募)
1 期
A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to the last prior therapy for their disease. - E7389-G000-211ocally advanced or metastatic breast cancerMedDRA version: 8.1 Level: PT Classification code 10055113
EUCTR2005-003656-35-GBEisai Limited300